Avalo Therapeutics (AVTX) Competitors $9.88 +0.51 (+5.44%) Closing price 04:00 PM EasternExtended Trading$9.80 -0.08 (-0.81%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTX vs. AUTL, PRME, ERAS, ETON, CGEM, TNXP, ITOS, GOSS, RGNX, and PRTAShould you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Autolus Therapeutics (AUTL), Prime Medicine (PRME), Erasca (ERAS), Eton Pharmaceuticals (ETON), Cullinan Therapeutics (CGEM), Tonix Pharmaceuticals (TNXP), iTeos Therapeutics (ITOS), Gossamer Bio (GOSS), REGENXBIO (RGNX), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry. Avalo Therapeutics vs. Its Competitors Autolus Therapeutics Prime Medicine Erasca Eton Pharmaceuticals Cullinan Therapeutics Tonix Pharmaceuticals iTeos Therapeutics Gossamer Bio REGENXBIO Prothena Avalo Therapeutics (NASDAQ:AVTX) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment. Do analysts rate AVTX or AUTL? Avalo Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 203.64%. Autolus Therapeutics has a consensus target price of $9.12, suggesting a potential upside of 421.14%. Given Autolus Therapeutics' higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than Avalo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, AVTX or AUTL? Avalo Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Does the media refer more to AVTX or AUTL? In the previous week, Autolus Therapeutics had 8 more articles in the media than Avalo Therapeutics. MarketBeat recorded 11 mentions for Autolus Therapeutics and 3 mentions for Avalo Therapeutics. Autolus Therapeutics' average media sentiment score of 0.91 beat Avalo Therapeutics' score of 0.68 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Autolus Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, AVTX or AUTL? Avalo Therapeutics has higher earnings, but lower revenue than Autolus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$440K295.28-$35.13MN/AN/AAutolus Therapeutics$10.12M46.02-$220.66M-$0.84-2.08 Do insiders and institutionals hold more shares of AVTX or AUTL? 87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 3.0% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is AVTX or AUTL more profitable? Avalo Therapeutics' return on equity of -48.48% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -48.48% -35.94% Autolus Therapeutics N/A -56.18%-29.61% SummaryAutolus Therapeutics beats Avalo Therapeutics on 7 of the 12 factors compared between the two stocks. Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTX vs. The Competition Export to ExcelMetricAvalo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$123.24M$2.80B$5.82B$9.73BDividend YieldN/A1.66%3.84%4.09%P/E RatioN/A22.6131.1525.97Price / Sales295.28751.84476.16171.70Price / CashN/A173.2237.1558.38Price / Book1.245.869.116.39Net Income-$35.13M$31.83M$3.26B$265.66M7 Day Performance9.53%1.80%2.11%1.98%1 Month Performance53.89%4.36%5.12%1.33%1 Year Performance16.92%11.44%31.25%21.15% Avalo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTXAvalo Therapeutics3.3815 of 5 stars$9.88+5.4%$30.00+203.6%+8.3%$123.24M$440K0.0040News CoverageAUTLAutolus Therapeutics3.127 of 5 stars$1.88+5.6%$9.12+385.1%-57.1%$473.73M$10.12M-2.24330Gap UpPRMEPrime Medicine2.9212 of 5 stars$3.50-2.0%$8.92+154.8%-26.8%$471.01M$4.96M-1.71234Gap UpERASErasca2.0116 of 5 stars$1.53-6.7%$4.29+180.1%-47.2%$465.22MN/A-3.40120ETONEton Pharmaceuticals2.4186 of 5 stars$16.37-3.9%$29.67+81.2%+312.8%$456.97M$39.01M-102.3120Positive NewsInsider TradeCGEMCullinan Therapeutics1.7856 of 5 stars$7.95+3.8%$28.60+259.7%-57.4%$452.51MN/A-2.4630News CoverageAnalyst ForecastAnalyst RevisionTNXPTonix Pharmaceuticals3.1649 of 5 stars$40.07-22.0%$70.00+74.7%-0.4%$450.13M$10.09M-1.0250High Trading VolumeITOSiTeos Therapeutics2.4092 of 5 stars$10.11flat$15.50+53.3%-41.7%$446.92M$35M-2.1690GOSSGossamer Bio3.3343 of 5 stars$1.99+1.5%$8.50+327.1%+130.9%$445.67M$114.70M-3.21180RGNXREGENXBIO4.3822 of 5 stars$8.71-1.2%$28.38+225.8%-33.6%$445.53M$155.78M-2.53370Analyst ForecastAnalyst RevisionPRTAProthena3.3286 of 5 stars$8.53+3.4%$30.25+254.6%-61.0%$444.10M$135.16M-1.51130 Related Companies and Tools Related Companies Autolus Therapeutics Competitors Prime Medicine Competitors Erasca Competitors Eton Pharmaceuticals Competitors Cullinan Therapeutics Competitors Tonix Pharmaceuticals Competitors iTeos Therapeutics Competitors Gossamer Bio Competitors REGENXBIO Competitors Prothena Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access